Lead Product(s): IkT-148x
Therapeutic Area: Neurology Product Name: IkT-148x
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
IkT-148x is c-Abl kinase inhibitor for treatment of Parkinson's disease and multiple system atrophy. A study revealed that c-Abl activates and regulates alpha-synuclein aggregation in the brains of MSA patients and in the brains of animal models of the disease.
Lead Product(s): IkT-148009
Therapeutic Area: Neurology Product Name: IkT-148009
Highest Development Status: IND Enabling Product Type: Small molecule
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 03, 2020
Inhibikase Therapeutics has filed two INDs for IkT-148009, one for PD and one for the treatment of PD-related gastrointestinal complications, and it expects to commence the first dosing of PD patients shortly after the conclusion of the offering.